← Back to Search

Other

1 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CPCRN RCT#2 Trial)

Phase 3
Waitlist Available
Research Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant has signed and dated the appropriate Informed Consent document.
Participant must have had symptoms of discomfort or pain in the pelvic region for at least a three (3) month period within the last six (6) months.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights

CPCRN RCT#2 Trial Summary

The purpose of this study is to determine whether pregabalin is an effective treatment for Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

Eligible Conditions
  • Chronic Prostatitis/Chronic Pelvic Pain Syndrome

CPCRN RCT#2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

CPCRN RCT#2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score
Secondary outcome measures
Global Response Assessment
Hospital Anxiety & Depression Scale
McGill Pain Questionnaire
+5 more

CPCRN RCT#2 Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: 1Active Control1 Intervention
Pregabalin
Group II: 2Placebo Group1 Intervention
Placebo

Find a Location

Who is running the clinical trial?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead Sponsor
2,338 Previous Clinical Trials
4,313,881 Total Patients Enrolled
John Kusek, PhDStudy DirectorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
4 Previous Clinical Trials
867 Total Patients Enrolled
Lee Nyberg, PhD, MDStudy DirectorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~17 spots leftby Mar 2025